http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018145098-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65705dca71d48b681c3aeb098ccd6291 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7246ac73b008ca0741a9b69f4feb2e17 |
| publicationDate | 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018145098-A |
| titleOfInvention | Novel immunosuppressant |
| abstract | [PROBLEMS] To develop a safer drug targeting calcineurin-NFAT signaling. An immunosuppressant comprising a compound represented by the following formula as an active ingredient. The above compounds exert immunosuppressive effects similar to 11R-VIVIT and FK506, and have a wider effective concentration range as drugs than 11R-VIVIT, and there is no impaired glucose tolerance as seen with FK506 Therefore, it can be expected as a safer drug (formula) X1-Sp-mR, (X1 is an amino acid sequence represented by KYELHAxTxxTPSVVVHVCxS; x is any natural amino acid; Sp is a spacer; ny; y is any (N is an integer from 0 to 5; R is arginine; m is an integer from 9 to 13). |
| priorityDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 132.